A total of 3303 healthy children and adolescents, aged 12 months to 17 years, were vaccinated with one of five production lots of a live attenuated varicella vaccine (VARIVAX) containing 1000 to 1625 plaque-forming units per dose. The vaccine was generally well tolerated. Ninety-six percent (2381/2475) of vaccinees responded to vaccination by producing antibody as measured by a glycoprotein-based enzyme-linked immunosorbent assay; 99% (569/576) of those tested maintained antibody at 1 year following vaccination. The incidence of varicella following household exposure in vaccinees was approximately 12%; household contact historically results in 87% infection. Nearly all of the vaccinees who had varicella after vaccination had a clinically modified disease.
Varicella Vaccine (VARIVAX) in Healthy Children and Adolescents: Results From Clinical Trials, 1987 to 1989
- Views Icon Views
- Share Icon Share
- Search Site
C. Jo White, Barbara J. Kuter, Carol S. Hildebrand, Kathryn L. Isganitis, Holly Matthews, Gary B. Calandra, William J. Miller, Philip J. Provost, Ronald W. Ellis, Robert J. Gerety; Varicella Vaccine (VARIVAX) in Healthy Children and Adolescents: Results From Clinical Trials, 1987 to 1989. Pediatrics May 1991; 87 (5): 604–610. 10.1542/peds.87.5.604
Download citation file: